FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Patients with chronic cardiovascular disease who receive automated reminders for their prescription blood pressure and cholesterol medications are more likely to refill those drugs.
A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
A Merck study found patients who received a cholesterol-lowering combination of ezetimibe/simvastatin experienced fewer major cardiovascular events than those taking simvastatin alone.
The FDA is taking a look at a trial that showed 30 months of dual antiplatelet blood-thinning therapy decreased the risk of heart attack and clot formation in stents, yet increased the overall risk of death compared with 12 months of the treatment.
Latest Issues
$auto_registration$